Drug Trial Radar · NCT06725758
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
315
Planned (sponsor's estimate)
Start
Oct 26, 2023
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Orion Corporation, Orion PharmaIndustry
- Sponsor type
- Industry
- First posted
- Dec 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours
Conditions
- Solid Tumours
Interventions
ODM-212Drug
ODM-212 5mg and/or 40mg tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and frequency of treatment emergent adverse events (TEAE)Time frame: From first dose to 1 year after LSLV
- Severity of TEAETime frame: From first dose to 1 year after LSLV
Locations
20 sites in 6 countries. Site status is shown where the registry gives one.
Valkyrie Clinical Trials
Los Angeles, California · Recruiting
UC Irvine Health
Orange, California · Recruiting
Siteman Cancer Center
St Louis, Missouri · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Westchester Medical Center
Valhalla, New York · Recruiting
Jefferson University Hospital
Philadelphia, Pennsylvania · Recruiting
University of Texas, MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Helsinki university Hospital
Helsinki, Finland · Recruiting
Oulu University Hospital
Oulu, Finland · Recruiting
Turku University Hospital
Turku, Finland · Recruiting
Institut Bergonie
Bordeaux, France · Recruiting
Centre Oscar Lambret
Lille, France · Recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
Hospital 12 de Octubre
Madrid, Spain · Recruiting
Hospital Virgen De La Macarena
Seville, Spain · Recruiting
Istituto Oncologico, Ospedale Bellinzona e Valli
Bellinzona, Canton Ticino, Switzerland · Recruiting
Leicester Royal Infirmary
Leicester, United Kingdom · Recruiting
Royal Marsden Hospital, London, UK
London, United Kingdom · Recruiting
Weston Park Hospital
Sheffield, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.